Pulmonary fibrosis modulation by mesenchymal stem cells and conditioned medium

Felix, R; Bovolato, Ana Livia Carvalho; Leão, Patricia dos Santos; Golim, Márjorie de Assis; Teodoro, Walcy Rosolia; Fabro, Alexandre Todorovic; Deffune, Elenice; Capelozzi, Vera Luíza

doi:10.1183/13993003.congress-2019.pa1284

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical and animal studies suggest it is as effective as pharmaceutical therapies in treating PF . Although they have uncertain mechanisms of action, MSCs have been proven to exert a modulating effect in lung inflammation and fibrosis . Experimental models on human tissue and animal studies have also reported that MSCs achieve excellent outcomes in ALI/ARDS by attenuating the severity of lung injury and by reducing mortality. , …”

Section: Discussionmentioning

confidence: 99%

“A Chain Only as Strong as Its Weakest Link”: An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19

Criṣan-Dabija

Pavel²,

Popa³

et al. 2020

J. Proteome Res.

View full text Add to dashboard Cite

The COVID-19 pandemic rapidly became a worldwide healthcare emergency affecting millions of people, with poor outcomes for patients with chronic conditions and enormous pressure on healthcare systems. Pulmonary fibrosis (PF) has been cited as a risk factor for a more severe evolution of COVID-19, primarily because its acute exacerbations are already associated with high mortality. We reviewed the available literature on biochemical, pathophysiological, and pharmacological mechanisms of PF and COVID-19 in an attempt to foresee the particular risk of infection and possible evolution of PF patients if infected with SARS-COV-2. We also analyzed the possible role of medication and risk factors (such as smoking) in the disease’s evolution and clinical course. We found out that there is a complexity of interactions between coexisting idiopathic pulmonary fibrosis/interstitial lung disease (ILD) and COVID-19 disease. Also, patients recovering from severe COVID-19 disease are at serious risk of developing PF. Smokers seem to have, in theory, a chance for a better outcome if they develop a severe form of COVID-19 but statistically are at much higher risk of dying if they become critically ill.

show abstract

Section: Discussionmentioning

confidence: 99%

“A Chain Only as Strong as Its Weakest Link”: An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19

Criṣan-Dabija

Pavel²,

Popa³

et al. 2020

J. Proteome Res.

View full text Add to dashboard Cite

show abstract

Mesenchyme Stem Cell-Derived Conditioned Medium as a Potential Therapeutic Tool in Idiopathic Pulmonary Fibrosis

Kolios

Paspaliaris²

2022

Biomedicines

View full text Add to dashboard Cite

Mesenchyme Stem Cells (MSCs) are the most used types of stem cells in regenerative medicine. Regenerative medicine is a rapidly emerging medicine section that creates new methods to regrow, restore, and replace diseased and damaged tissues, organs, and cells. Scholars have shown a positive correlation between MSCs-based therapies and successful treatment of diseases like cardiac ischemia, cartilage problems, bone diseases, diabetes, and even neurological disorders. Although MSCs have several varying features that make them unique, their immuno-regulatory effects in tissue repair emerge from their secretion of paracrine growth factors, exosomes, and cytokines. These cells secrete a secretome, which has regenerative and reparative properties that lead to injury amelioration, immune modulation, or fibrosis reduction. Recent studies have shown that the administration MCSs derived conditioned medium (MSCs-CM) in acute doses in humans is safe and well-tolerated. Studies from animal models and human clinical trials have also shown that they are efficacious tools in regenerative medicine. In this review, we will explore the therapeutic potential of MSCs-CM in pulmonary fibrosis, with further insight into the treatment of Idiopathic Pulmonary Fibrosis (IPF).

show abstract

Pulmonary fibrosis modulation by mesenchymal stem cells and conditioned medium

Cited by 2 publications

References 0 publications

“A Chain Only as Strong as Its Weakest Link”: An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19

“A Chain Only as Strong as Its Weakest Link”: An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19

Mesenchyme Stem Cell-Derived Conditioned Medium as a Potential Therapeutic Tool in Idiopathic Pulmonary Fibrosis

Contact Info

Product

Resources

About